Introduction
============

Telavancin (TLV) is an investigational lipoglycopeptide with activity against Gram-positive pathogens. The Assessment of Telavancin for Treatment of Hospital-acquired Pneumonia (ATTAIN) programme studied TLV for the treatment of hospital-acquired pneumonia (HAP). This analysis compared the clinical cure rates achieved with TLV or vancomycin (VAN) for severely ill and older patients.

Methods
=======

ATTAIN 1 and ATTAIN 2 were methodologically identical, randomised, double-blind, phase 3 studies. Adult patients with pneumonia acquired after 48 hours in an inpatient acute-care or chronic-care facility, or acquired within 7 days after being discharged following ≥ 3 days of hospital stay were randomised to TLV 10 mg/kg intravenously every 24 hours or VAN 1 g intravenously every 12 hours for 7 to 21 days. A test-of-cure (TOC) visit was conducted 7 to 14 days after end-of-study treatment. Compliant patients who had a clinical response of either cure or failure at TOC were considered clinically evaluable (CE).

Results
=======

Pooled clinical cure rates at TOC for several clinically relevant subgroups including the elderly as well as patients with severe HAP at baseline are presented in Figure [1](#F1){ref-type="fig"}. The percentage of patients reporting at least one treatment-emergent adverse event was comparable between the TLV and VAN groups (80% vs. 79%, respectively).
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Conclusion
==========

Although not statistically significant, TLV achieved numerically higher cure rates than VAN for treatment of HAP in severely ill and older patients with comparable treatment-emergent adverse events.
